Colorectal Cancer: Page 4

Clinics begin adopting Genetic Technologies risk test
By LabPulse.com staff writers
The clinics can focus on testing for a single disease or multiple diseases, including breast cancer, colorectal cancer, ovarian cancer, coronary artery disease, prostate cancer, and type 2 diabetes, the company said.
June 30, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Guardant releases colorectal cancer blood test
By LabPulse.com staff writers
In a validation effort using 309 patient samples (including 92 with colorectal cancer), the Shield test showed a sensitivity of 91% and a specificity of 92% for detecting colorectal cancer. It is intended for adults 45 years and older who are not current with screening recommendations, are asymptomatic, and are at average risk for the disease.
May 1, 2022
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Guardant highlights data on multicancer test at AACR 2022
By LabPulse.com staff writers
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
2017 09 14 23 05 1167 Cancer Cell 400
Guardant wins new clearances in Japan for liquid biopsy test
By LabPulse.com staff writers
The MHLW has cleared Guardant360 CDx for mutation profiling in patients with advanced solid tumors. In addition, it approved Guardant360 CDx as a companion diagnostic for identifying patients with microsatellite instability-high solid tumors who may benefit from pembrolizumab (Keytruda). What's more, Guardant360 CDx has also been approved for patients with MSI-High advanced colorectal cancer who may benefit from nivolumab (Opdivo).
March 14, 2022
2022 03 08 19 56 8772 Clearance Stamp 400
No advantage for ctDNA assay for monitoring colorectal cancer
By Rebekah Moan
A research team led by Dr. Marwan Fakih at the City of Hope Comprehensive Cancer Center in Duarte, CA, sought to determine which technique is superior in identifying residual disease and early cancer recurrence: Natera's Signatera ctDNA assay or CT scans and a CEA blood draw. They found the National Comprehensive Cancer Network's (NCCN) current standard of care (CT scans and a CEA blood draw) had higher sensitivity than the assay (JAMA Network Open, March 8, 2022, Vol. 5:3, e221093).
March 9, 2022
2022 03 10 00 18 3072 2022 03 10 Ct Dna Fakih Marwan 400 20220310005244
FDA clears Foundation Medicine's companion diagnostic
By LabPulse.com staff writers
Characterizing these tumors helps clinicians identify patients who could benefit from immunotherapy such as Keytruda, a humanized antibody used in cancer immunotherapy, the company said. MSI-H status is a defining feature of colorectal, endometrial, and gastrointestinal cancers.
February 22, 2022
2019 02 13 19 24 5396 Fda Logo V2 400
Guardant touts studies on liquid biopsy tests at ASCO meeting
By LabPulse.com staff writers
Data from a large, prospective, observational study shows that Guardant Reveal can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time greater than six months when performed after curative intent surgery for stage II-III colorectal cancer, Guardant said.
January 19, 2022
2020 06 01 18 51 2022 Cancer Lung 400
Natera to expand into early cancer detection
By LabPulse.com staff writers
In November 2021, Natera announced exclusive access from Aarhus University to a biobank of up to 40,000 prospectively collected colorectal cancer screening samples for the development and validation of Natera's early cancer detection products. The database of samples is expected to help accelerate the introduction of Natera's products to market and potentially support key commercial milestones, the company said.
January 5, 2022
2019 10 09 17 32 0093 Dna Cancer Cell 400
Lab Genomics, Canexia secure MolDX coverage for DNA assay
By LabPulse.com staff writers
The decision allows for Medicare coverage of Follow It for breast, lung, and colorectal cancers, the two firms said. Follow It can help guide cancer treatment, according to the companies.
November 1, 2021
2021 01 12 23 44 3780 Blood Test Samples Lab 400
DiaCarta touts results from ColoScape assay in colon cancer
By LabPulse.com staff writers
DiaCarta's ColoScape xenonucleic acid (XNA)-mediated quantitative real-time polymerase chain reaction clamping assay targets 19 mutations in a panel of genes linked with early precancerous colorectal cancer lesions. ColoScape detects mutant cell-free DNA (cfDNA) mutations with high sensitivity, according to the results.
October 26, 2021
2019 10 01 18 58 9423 Colon2 400
Promega's OncoMate MSI system cleared by FDA
By LabPulse.com staff writers
With the FDA clearance, the company said oncologists and pathologists in the U.S. can now access the IVD test that screens for Lynch syndrome in patients with colorectal cancer.
July 29, 2021
2019 05 22 19 44 5254 Dna Red Laser 400
NuProbe announces new DNA microsatellite instability assay
By LabPulse.com staff writers
The condition is present in about 15% of colorectal cancer patients and 30% of endometrial cancer patients, and is associated with better immunotherapy response and survival rates, according to the firm. But identifying MSI can be difficult using quantitative polymerase chain reaction (qPCR) testing, the company said. Its assay consists of a thermodynamic model of DNA microsatellite binding that boosts the effectiveness of qPCR testing.
July 25, 2021
2019 04 19 17 18 7022 Dna Strand 400
Previous Page
Page 4 of 6
Next Page